U.S. Lawmakers Push Eli Lilly to Explain China Drug Trials Linked to Military
The House Select Committee on the Chinese Communist Party has launched an investigation into pharmaceutical giant Eli Lilly’s clinical trial operations in China, where trials are taking place at military-linked hospitals and facilities in Xinjiang.
Chairman John Moolenaar is leading the probe, citing concerns about biotech risks and potential implications for national security. The investigation targets Eli Lilly’s decision to conduct clinical trials at the military hospitals and in the Xinjiang region, where the Chinese government has been accused of human rights abuses.
Concerns Over Data Security and Human Rights
The House committee’s investigation is fueled by worries that sensitive data, including information about new treatments and drugs, may be compromised by conducting trials in these locations. China’s strict data protection laws allow for surveillance and access to sensitive information by the government and the military.
Additionally, the committee is looking into whether Eli Lilly is adhering to international ethics guidelines and respecting the rights of trial participants. The Xinjiang region has been the site of numerous reports of human rights abuses, including forced labor and ethnic cleansing. Eli Lilly’s involvement in the region raises questions about the company’s commitment to human rights and its willingness to conduct business in areas with questionable ethics.
Eli Lilly’s Response: Transparency and Compliance
Eli Lilly has released a statement claiming that it takes the concerns raised by the House committee seriously and is committed to transparency and compliance with international standards. The company asserts that all its clinical trials, including those in China, adhere to the principles of good clinical practice and respect human rights.
However, the House committee has requested information from Eli Lilly, including details about the company’s trial protocols, the locations of its trials in China, and the measures it takes to ensure data security and protect the rights of trial participants. The company has until the end of July to provide the requested information.
What This Means
The House committee’s investigation into Eli Lilly’s China clinical trials is a significant development in the ongoing tensions between the U.S. and China over biotech and data security. This probe highlights the risks and complexities involved in conducting clinical trials in countries with varying levels of data protection and human rights standards.
